Chemotactic CD34+ Stem Cell Composition for Vascular Injury Repair

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current therapies are inadequate for preventing long-term adverse consequences of vascular insufficiency, particularly myocardial infarction, as they fail to effectively address the damage and remodeling post-myocardial infarction, leading to persistent cardiac dysfunction and increased risk of adverse cardiac events.

Innovation Solution

A sterile pharmaceutical composition comprising a chemotactic hematopoietic stem cell product enriched with CD34+ cells, which are isolated, purified, and formulated to maintain viability and chemotactic activity, allowing them to home to and repair sites of vascular insufficiency, including infarcted myocardium.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If conventional therapies are used for myocardial infarction, then immediate cardiac function is restored through reperfusion, but long-term cardiac dysfunction persists due to ventricular remodeling and fibrotic scarring

Engineering Contradiction:

Improvelong-term cardiac functionVSAvoidpersistent cardiac dysfunction

Core Design Contradiction:

ReliabilityVSDuration of action of stationary object

Solution Approach 1:

The patent administers hematopoietic stem cells at a specific time window (5-14 days post-infarction) before irreversible ventricular remodeling and fibrotic scarring occur. This preliminary action allows the stem cells to home to the injured myocardium and promote endogenous repair mechanisms, preventing long-term cardiac dysfunction before it fully develops

Inventive Principle:

Principle #10Preliminary action

Solution Approach 2:

The administered hematopoietic stem cells utilize the body's own chemotactic signals (SDF-1) and natural repair mechanisms to migrate to and repair the injured myocardium. The stem cells differentiate into cardiac progenitor cells that integrate with existing tissue and promote endogenous regeneration, allowing the body's own systems to service the repair process

Inventive Principle:

Principle #25Self-service

2Productivity

If rapid reperfusion is performed to limit infarct size, then immediate myocardial salvage is achieved, but long-term adverse cardiac events increase due to ventricular remodeling

Engineering Contradiction:

Improvemyocardial salvage rateVSAvoidventricular remodeling

Core Design Contradiction:

ProductivityVSObject-affected harmful factors

Solution Approach 1:

The patent converts the harmful process of ventricular remodeling and fibrotic scarring into a beneficial repair process by administering hematopoietic stem cells that home to the injured myocardium. These cells differentiate into cardiac progenitor cells that promote tissue regeneration and functional recovery, transforming the normally harmful remodeling process into a beneficial repair mechanism

Inventive Principle:

Principle #22Blessing in disguise (Convert harm into benefit)

Solution Approach 2:

The hematopoietic stem cells act as intermediary agents between the damaged myocardium and the body's natural repair mechanisms. They respond to chemotactic signals (SDF-1) from the injured tissue, migrate to the site of injury, and facilitate repair through differentiation into cardiac progenitor cells, serving as a bridge between reperfusion and long-term functional recovery

Inventive Principle:

Principle #24Intermediary (Mediator)

3Measurement precision

If CD34+ cells are isolated and purified for therapy, then chemotactic activity and homing efficiency are enhanced, but manufacturing complexity and processing time increase

Engineering Contradiction:

Improvecell homing efficiencyVSAvoidcell isolation process

Core Design Contradiction:

Measurement precisionVSDevice complexity

Solution Approach 1:

The patent extracts and isolates the specific CD34+ hematopoietic stem cell population from whole bone marrow or peripheral blood using immunomagnetic bead separation or fluorescence-activated cell sorting. This extraction of the therapeutically active cell population enhances homing efficiency to the injured myocardium while removing non-functional cell types that would dilute the therapeutic effect

Inventive Principle:

Principle #2Taking out (Extraction)

Solution Approach 2:

The patent changes the physical and chemical parameters of the cell preparation process by using immunomagnetic beads or fluorescent markers to identify and separate CD34+ cells based on their surface markers. This parameter-based separation (using magnetic properties or fluorescence) enables precise isolation of the therapeutic cell population while managing manufacturing complexity through standardized protocols

Inventive Principle:

Principle #35Parameter changes

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The composition enables potent CD34+ cells to migrate to injury sites, promoting repair and potentially limiting damage, thereby improving cardiac function and reducing the risk of long-term cardiac dysfunction.

Implementation Method 1

a chemotactic hematopoietic stem cell product comprising an enriched population of isolated CD34+ cells containing a subpopulation of cells having chemotactic activity

Methodology Applied

Scientific EffectChemotaxis:

Data Source

PatentEP1951864B1Compositions and methods of vascular injury repair

Publication Date: 2014.05.07 AMORCYTE INC

Figure 1
Figure 2
Figure 3

AI summary

The present invention relates to pharmaceutical compositions comprising a chemotactic hematopoietic stem cell product comprising an enriched population of CD34+ cells containing a subpopulation of cells having chemotactic activity, methods of preparing these compositions and use of these compositions to treat or repair vascular injury, including infarcted myocardium.